Focused On-demand Library for Beta-citrylglutamate synthase B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9ULI2

UPID:

RIMKB_HUMAN

Alternative names:

N-acetyl-aspartylglutamate synthetase B; Ribosomal protein S6 modification-like protein B

Alternative UPACC:

Q9ULI2; B7Z834; D3DUV2; Q8N4P4; Q8WTW6

Background:

Beta-citrylglutamate synthase B, also known as N-acetyl-aspartylglutamate synthetase B and Ribosomal protein S6 modification-like protein B, plays a crucial role in the synthesis of beta-citryl-L-glutamate and N-acetyl-L-aspartyl-L-glutamate, with a preference for the former. This enzyme's activity is pivotal in the metabolism of specific amino acids.

Therapeutic significance:

Understanding the role of Beta-citrylglutamate synthase B could open doors to potential therapeutic strategies. Its involvement in amino acid metabolism highlights its importance in maintaining cellular health and offers a promising avenue for exploring novel treatments.